We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Using Nucleic Acids From Urine for Diagnostics

By Labmedica staff writers
Posted on 20 Oct 2006
A new method for the isolation of cell-free nucleic acids from urine is simple, cost-effective, applicable to small and large volumes of urine, and can be used for transrenal (Tr)-DNA preservation, storage, purification, and diagnostic tests.

The new method for the isolation of low-molecular-weight cell-free Tr-DNA from urine was developed by Xenomics (New York, NY, USA). More...
Using this new approach, Xenomics is planning to develop kits to accelerate the application of its Tr-DNA technology in different areas of DNA-based molecular diagnostics, in both humans as well as animals. Similar products will be developed for clinical diagnostic tests, based on an analysis of Tr-DNA.

"This new method of DNA isolation from urine specimens is an important milestone for Xenomics,” commented Dr. L. David Tomei, CEO and co-founder of Xenomics. "Many of the available DNA isolation kits were designed for purification of large genomic DNA in blood or tissue specimens. The new techniques are specifically designed to isolate Tr-DNA from simple urine specimens, and used to detect the genetic signature of a broad variety of diseases in the body.”

Obtaining urine is simple and does not involve invasive procedures. In addition, it can be sampled easily in both children and adults. Small DNA markers in urine specimens can come from throughout the body and are clearly distinct from the body's genetic makeup. Xenomics aims to apply its Tr-DNA test platform to develop highly sensitive, truly non-invasive molecular diagnostics, which will replace outdated blood, sputum, and tissue testing technologies, many of which are not sufficiently sensitive or specific and are often hazardous and difficult to automate.



Related Links:
Xenomics

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.